Literature DB >> 6721521

Dermal collagen degradation and phagocytosis. Occurrence in a horse with hyperextensible fragile skin.

D E Gunson, R E Halliwell, R R Minor.   

Abstract

A 2-year-old female horse had large areas of hyperextensible, fragile skin that were interspersed with areas of normal skin. Affected skin tore easily and contained reduced amounts of dermal collagen. Collagen fibers were fragmented and disorganized, and in trichrome-stained sections, many fibers had abnormal red-stained centers. Electron microscopy showed that many collagen fibers had discrete foci of degradation in which the fibrils were fragmented, loosely packed, and widely separated by granular material. Collagen fibril fragments were present in secondary lysosomes in dermal fibroblasts, but there were no degranulated mast cells or inflammatory cells in these areas. This suggested that a noninflammatory degradation and phagocytosis of collagen had occurred in the areas of hyperextensible fragile skin in this horse. Unaffected skin had no signs of collagen degradation or phagocytosis; uniformly cylindrical collagen fibrils were densely packed into morphologically normal fibers.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6721521

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  2 in total

1.  Skin malformations in a neonatal foal tested homozygous positive for Warmblood Fragile Foal Syndrome.

Authors:  Chloé Monthoux; Simone de Brot; Michelle Jackson; Ulrich Bleul; Jasmin Walter
Journal:  BMC Vet Res       Date:  2015-01-31       Impact factor: 2.741

2.  Distribution of the Warmblood Fragile Foal Syndrome Type 1 Mutation (PLOD1 c.2032G>A) in Different Horse Breeds from Europe and the United States.

Authors:  Simone Reiter; Barbara Wallner; Gottfried Brem; Elisabeth Haring; Ludwig Hoelzle; Monika Stefaniuk-Szmukier; Bogusława Długosz; Katarzyna Piórkowska; Katarzyna Ropka-Molik; Julia Malvick; Maria Cecilia T Penedo; Rebecca R Bellone
Journal:  Genes (Basel)       Date:  2020-12-18       Impact factor: 4.096

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.